EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Cogent Biosciences, Inc. (COGT) EBITDA Margin data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-328.94M |
|
-- |
|
-- |
|
$333.36M |
|
$-333.36M |
|
$4.43M |
|
$-328.94M |
|
$-328.94M |
|
$-328.94M |
|
$-328.94M |
|
$-328.94M |
|
$-328.94M |
|
$-333.36M |
|
$-332.16M |
|
128.90M |
|
128.90M |
|
$-2.16 |
|
$-2.16 |
|
| Balance Sheet Financials | |
$910.36M |
|
$5.46M |
|
$27.25M |
|
$937.61M |
|
$63.95M |
|
$222.90M |
|
$237.28M |
|
$301.24M |
|
$546.98M |
|
$636.37M |
|
$636.37M |
|
160.98M |
|
| Cash Flow Statement Financials | |
$-264.44M |
|
$-399.53M |
|
$878.23M |
|
$98.17M |
|
$312.43M |
|
$214.26M |
|
$46.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.23 |
|
-- |
|
-- |
|
0.26 |
|
0.35 |
|
-- |
|
-- |
|
-- |
|
|
EBITDA Margin |
-- |
-- |
|
-- |
|
$-266.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-60.14% |
|
-51.69% |
|
-35.08% |
|
-38.28% |
|
$3.95 |
|
$-2.06 |
|
$-2.05 |
|